i-SENS, Inc. 099190

KRX · South Korea · Health Technology

KRW 17,260.00+1,450.00 (+9.17%)

Market closed· Oct 1, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

i-SENS, Inc. 099190

KRX · South Korea · Health Technology

KRW 17,260.00+1,450.00 (+9.17%)

Market closed· Oct 1, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-12.03% · 6MFull-screen chart

Open KRW 15,960.00High KRW 17,550.00Low KRW 15,880.00Close KRW 17,260.00Volume 104.20K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 15,810.00
Volume: 0
Market cap: KRW 467.54B
Dividend yield (annualized): 0.63%
Next earnings date: 2026-11-18
Avg. volume (1Y): 132.39K

Performance

1 week

+8.35%

1 month

-0.40%

3 months

+7.94%

6 months

-5.06%

Year to date

+7.54%

1 year

-10.14%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Medical Specialties
Country: South Korea
Exchange: KRX
Shares outstanding: 29.57M
Employees: 957
ISIN: KR7099190001
Beta: 0.43

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceMar 23, 2026

CoaguSense Announces Agreement to Acquire DOASENSE DOAC Testing Business, Expanding Leadership in Anticoagulation Monitoring

FREMONT, Calif., March 22, 2026 (GLOBE NEWSWIRE) -- CoaguSense, Inc., a leading developer of point-of-care coagulation monitoring systems and a subsidiary of i-SENS, Inc. (KOSDAQ: 099190), today announced it has entered into a definitive asset purchase agreement to acquire the business of DOASENSE GmbH, Heidelberg, a pioneer in specialized diagnostic solutions for Direct Oral Anticoagulants (DOACs). This strategic acquisition is designed to expand CoaguSense’s portfolio beyond traditional Vitami

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.